A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization

American Journal of Transplantation

Volumn 9, Issue 8, 2009, Pages 1920-1928

  Lewandowski, R J ^a   Kulik, L M ^b   Riaz, A ^a   Senthilnathan, S ^a   Mulcahy, M F ^b   Ryu, R K ^a   Ibrahim, S M ^a   Sato, K T ^a   Baker, T ^c   Miller, F H ^a   Omary, R ^a   Abecassis, M ^c   Salem, R ^a,b,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemoembolization; Downstaging; Hepatocellular carcinoma; Radioembolization; Yttrium 90 microspheres

Indexed keywords

CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 67650938388     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02695.x     Document Type: Article

References (33)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology (Baltimore, MD) 2002 36 (5 Suppl 1 S74 S83.
2. Detry O, De Roover A, Delwaide J, Meurisse M, Honore P. Absolute and relative contraindications to liver transplantation. A perpetually moving frontier. Acta Gastroenterol Belg 2002 65 : 133 134.
3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
4. Sharma P, Balan V, Hernandez JL et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl 2004 10 : 36 41.
5. Gunji T, Kawauchi N, Akahane M, Watanabe K, Kanamori H, Ohnishi S. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma. Int J Oncol 2002 21 : 427 432.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003 37 : 429 442.
7. Pulvirenti A, Garbagnati F, Regalia E et al. Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. Transplant Proc 2001 33 : 1516 1517. (Pubitemid 32237955)
8. Vaughan AT, Anderson P, Dykes PW, Chapman CE, Bradwell AR. Limitations to the killing of tumours using radiolabelled antibodies. Br J Radiol 1987 60 : 567 572.
9. Bharat A, Brown DB, Crippin JS et al. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve long term survival. J Am Coll Surg 2006 203 : 411 420.
10. Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008 13 : 234 240.
11. Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005 11 : 1505 1514.
12. Otto G, Herber S, Heise M et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006 12 : 1260 1267.
13. Yao FY. Liver transplantation for hepatocellular carcinoma: Beyond the Milan criteria. Am J Transplant 2008 8 : 1982 1989.
14. Fukumitsu N, Sugahara S, Nakayama H et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009 Mar 20 [Epub ahead of print].
15. TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada. 2004.
16. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: Radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002 13 (9 Pt 2 S223 229.
17. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006 17 : 1251 1278. (Pubitemid 44259009)
18. Pompili M, Mirante VG, Rondinara G et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005 11 : 1117 1126.
19. Forner A, Ayuso C, Varela M et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2008 115 : 616 623.
20. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008 100 : 698 711.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457 481.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, MD) 2005 42 : 1208 1236.
23. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 430.
24. Lo C. Downstaging of hepatocellular carcinoma before transplantation: An advance in therapy or just another selection criterion. Am J Transplant 2008 8 : 2485 2486.
25. Dawson LA, Guha C. Hepatocellular carcinoma: Radiation therapy. Cancer J 2008 14 : 111 116.
26. Kulik LM, Atassi B, van Holsbeeck L et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006 94 : 572 586.
27. Heckman JT, Devera MB, Marsh JW et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol 2008 15 : 3169 3177.
28. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 359 : 378 390.
29. Goin JE, Dancey JE, Roberts CA, Sickles CJ, Leung DA, Soulen MC. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: Trans-catheter arterial chemo-embolization versus Yttrium-90 glass microspheres. World J Nuc Med 2004 3 : 49 56.
30. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009 10 : 35 43.
31. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002 359 : 1734 1739.
32. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 35 : 1164 1171.
33. Freeman RB Jr., Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008 8 (4 Pt 2 958 976.